AbbVie just wrote a $10.9 billion check for a drug that hasn't been approved yet, and the bet hinges on a simple premise: people hate getting injections every two weeks.

The pharmaceutical giant announced Monday it would acquire biotech Apogee Therapeutics in its largest deal in more than five years. The prize is zumilokibart, an experimental treatment for inflammatory diseases including moderate-to-severe atopic dermatitis (the kind of chronic, painful eczema that affects millions of Americans) and asthma. Unlike the current leading treatment, Dupixent from Sanofi and Regeneron, which requires an injection every two weeks, zumilokibart is being studied as a shot given once every three to six months. AbbVie is betting that difference is worth nearly eleven billion dollars.

Why this deal, and why now

AbbVie built its empire on Humira, a blockbuster drug for autoimmune conditions that was once the best-selling medicine in the world. When its patent protection ran out and cheaper copies flooded the market, Humira sales dropped 49% last year. AbbVie has been scrambling to replace that revenue ever since, leaning hard on two newer immunology drugs, Skyrizi and Rinvoq, which together helped push the company's immunology revenue above $30 billion in 2025. But those drugs face their own patent expiration cliffs in the coming years, and AbbVie needs to build the next generation of treatments now, while it still has the cash to do it.

The Apogee deal follows the same playbook AbbVie used with ImmunoGen (a $10.1 billion acquisition for an ovarian cancer drug) and Cerevel Therapeutics (bought for its experimental neurological treatments). Buy early. Pay a premium. Own the pipeline before the pipeline matures.

AbbVie paid $135.11 per Apogee share, a premium of nearly 50% over where the stock was trading before the deal was announced. Apogee's shares jumped 47% in premarket trading. AbbVie's rose about 1.5%, a signal that investors see the price as steep but defensible.

What this means for patients

If zumilokibart clears clinical trials and wins FDA approval, it could meaningfully change the treatment experience for people living with severe eczema or asthma. Dupixent is effective, but a biweekly injection schedule is a real burden, especially for people managing chronic conditions over years or decades. A shot every three to six months is a different kind of relationship with your medicine.

RBC Capital analyst Brian Abrahams called AbbVie "an ideal acquirer to maximize zumilokibart's potential," noting the drug targets a large and growing market and its infrequent dosing is a genuine competitive advantage over existing therapies.

That said, zumilokibart is still experimental. AbbVie says the deal won't add to its earnings per share until 2032, which means the company is looking at least six years out before the financial return kicks in. A lot can go wrong in drug development between now and then.

The bigger pattern

This deal is part of a broad wave of pharmaceutical acquisitions driven by one looming reality: the U.S. government's new authority to negotiate drug prices directly with Medicare, combined with a wave of patent expirations, is squeezing future revenue for nearly every major drugmaker. Companies that once sat on blockbuster monopolies are now racing to refill their pipelines before the gap becomes a crater.

For ordinary people, the dynamic cuts two ways. Competition in immunology drugs is genuinely good news. Dupixent made Sanofi and Regeneron rich precisely because it had no real rival for years. A well-funded challenger with a more convenient dosing schedule could eventually push prices down or at least give insurers and patients real leverage.

But the $10.9 billion price tag will eventually land somewhere, and in the American pharmaceutical market, it usually lands on the patient.